{{one source|date=August 2014}}
{{Drugbox
| Verifiedfields = changed
| verifiedrevid = 447729255
| image = Mertansine mab structure.svg
<!-- Monoclonal antibody data -->
| type = mab
| mab_type = mab
| source = zu/o
| target = [[CD44]] v6
<!-- Clinical data -->
| tradename = 
| pregnancy_AU = 
| pregnancy_US = 
| pregnancy_category = 
| legal_AU = 
| legal_CA = 
| legal_UK = 
| legal_US = 
| legal_status = 
| routes_of_administration = 
<!-- Pharmacokinetic data -->
| bioavailability = 
| protein_bound = 
| metabolism = 
| elimination_half-life = 
| excretion = 
<!-- Identifiers -->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 
| ATC_prefix = none
| ATC_suffix = 
| PubChem = 
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = 
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = none
<!-- Chemical data -->
| chemical_formula = 
| molecular_weight = 
}}
'''Bivatuzumab mertansine''' is a combination of [[bivatuzumab]], a [[humanized monoclonal antibody]], and [[mertansine]], a [[cytotoxic agent]]. It is designed for the treatment of [[squamous cell carcinoma]].<ref>{{cite journal|doi=10.1158/1078-0432.CCR-06-0910|pmid=17062682|year=2006|last1=Tijink|first1=BM|last2=Buter|first2=J|last3=De Bree|first3=R|last4=Giaccone|first4=G|last5=Lang|first5=MS|last6=Staab|first6=A|last7=Leemans|first7=CR|last8=Van Dongen|first8=GA|title=A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus|volume=12|issue=20 Pt 1|pages=6064â€“72|journal=Clinical Cancer Research}}</ref>

==References==
{{reflist}}

{{Monoclonals for tumors}}

[[Category:Monoclonal antibodies for tumors]]
[[Category:Experimental cancer drugs]]


{{monoclonal-antibody-stub}}
{{antineoplastic-drug-stub}}